Translate page

Flagge BrasilienMay 2022 - Questions about CML management during the COVID-19 pandemic remain highly relevant for clinical practice. To provide physicians treating CML around the world with best possible support, we are hosting expert talks on CML and COVID-19 management in French, Portuguese, Spanish and Russian.

If you speak Portuguese, join us for the live expert talk in Portuguese on May 31st at 8.30 AM Brazilian Time with Dr Katia Pagnano from Brazil. You will learn how to best treat your patients with CML and COVID-19 and get the latest updates on COVID-19 vaccines for patients with CML.

As a reminder the presentation on COVID-19 and CML in French is available here

CoronavirusApril 2022 - We are delighted to share that a first sub-analysis of the iCMLf CML and COVID-19 CANDID data has been accepted as a clinical poster presentation for the EHA 2022 Congress in June:

COVID-19 in patients with chronic myeloid leukemia in treatment-free remission:
Disease-severity and impact on TFR status (Saußele S et al. EHA 2022 abstract no. 1886)

The sub-analysis of the CANDID study aimed to evaluate the outcome of SARS-CoV-2 infection in CML patients in treatment-free remission and assessed any impact on maintenance of TFR. Additional information were collected for this analysis including: molecular remission status before, during and after COVID-19 infection.

We look forward to seeing you at EHA and sharing more details.

Genomics Alliance Logo

April 2022 - The iCMLf Genomics Alliance is now partnering with the HARMONY Big Data platform to analyse genetic data from thousands of CML patients. A novel iCMLf Genomics Alliance research project, led by Professor Thomas Ernst (University Hospital Jena, Germany) will study the role of genetic aberrations in the disease course of CML.

'A goal of the iCMLf Genomics Alliance is to pool mutatational data through a shared database. This will enhance statistical power in order to understand the impact of genomic variation on treatment response for patients with CML' (Sue Branford – Chair of the iCMLf Genomics Alliance)

The iCMLf is leading the way to bring the CML community together to contribute genomic and clinical data to the HARMONY Plus database and use ‘Big Data’ to answer key questions in CML. The first project aims to elucidate the hierarchy of genomic events that underlie the disease course in CML. Sites from Australia, Canada, Czech Republic, Germany, Italy, Russia, Spain, Taiwan, UK and USA are currently entering data for the project.

We welcome further interest from groups to contribute data, or ideas for future analysis.

CD5038 Conversations tile 27x12813946March 2022 - The iCMLf Conversations on CML have developed into one of our key educational programs. So far, we have hosted 24 live expert discussions with 37 experts, covering a wide a range of topics around CML management.

All expert discussions are now available to view on-demand on the iCMLf website and the presentations have been viewed more than 8,000 times so far.

We are also delighted to share that we will continue with these expert discussions this year. Over the next couple of months we will be hosting monthly live webinars with renowned experts in the field that cover a wide range of relevant topics for your clinical practice. Be excited!

Oliver HantschelMarch 2022 - The iCMLf awards the 2022 Rowley Prize to Professor Oliver Hantschel, for his scientific research on structural biochemistry of tyrosine kinase oncoproteins that helped to describe novel targetable pathways in the pathophysiology of BCR-ABL. The Rowley Prize is awarded to celebrate people who have made outstanding lifetime contributions to the understanding of the biology of CML.

Andreas Hochhaus

March 2022 - We are delighted to announce Professor Andreas Hochhaus, Head of the Department of Hematology and Medical Oncology at Jena University Hospital as the 2022 Goldman Prize recipient. He receives the prize in recognition of his outstanding clinical leadership in CML and for his lifelong contributions to the optimization of CML therapy – through his work on mechanisms of resistance and stem cell persistence, through leading clinical studies and through the development of clinical recommendations. The annual Goldman Prize awarded in honour of Professor John Goldman, acknowledges outstanding lifetime contributions to the management of patients with CML.